November 3, 2023 – Page 6

BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®

Written by Customer Service on November 3, 2023. Posted in Public Companies.

– SCS Microinjector is the first and only FDA-approved approach to access the suprachoroidal space – – BioCryst to host R&D Day today at 1:00 pm ET – ALPHARETTA, Ga. and RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2023 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Clearside Biomedical, Inc. (Nasdaq: CLSD) today announced the entry into a license agreement enabling BioCryst to develop its investigational plasma kallikrein inhibitor, avoralstat, with Clearside’s SCS Microinjector® to deliver avoralstat directly to the back of the eye through the suprachoroidal space to treat patients with diabetic macular edema (DME). “Many DME patients are not effectively controlled with anti-VEGF therapy, so it is exciting to target plasma kallikrein by combining avoralstat with delivery into the suprachoroidal space using...

Zealand Pharma conference call on November 9 at 2pm CET (8am ET) to present third quarter 2023 results

Written by Customer Service on November 3, 2023. Posted in Public Companies.

Press Release – No. 14 / 2023 Zealand Pharma conference call on November 9 at 2pm CET (8am ET) to present third quarter 2023 results Copenhagen, Denmark, November 3, 2023 – a Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on November 9, 2023, at 2:00 pm CET (8:00 am ET) following the announcement of results for the third quarter and first nine months of 2023. Presenting during the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; and Chief Medical Officer, David Kendall. The presentation will be followed by a Q&A session, and both will be conducted in English. Telephone dial-in information and a unique personal access PIN will be...

Sdiptech AB (publ) – Parts of the management in Sdiptech AB (publ) sell shares to cover tax debt

Written by Customer Service on November 3, 2023. Posted in Public Companies.

Press release3 November 2023, 17:00 Parts of the management in Sdiptech AB (publ) sell shares to cover tax debt Today, Sdiptech announces that parts of the company’s management team have sold B-shares to cover tax debt. With the redemption of previous warrant programs, which have resulted in taxation of the holders, some warrant holders from the management have now sold a number of shares to cover these tax payments. In total, it comprises 59,000 B shares, the distribution of which is stated in the upcoming insider reporting. For additional information, please contact:Bengt Lejdström, CFO, +46 702 74 22 00, bengt.lejdstrom@sdiptech.com Sdiptech’s common shares of series B are traded on Nasdaq Stockholm under the short name SDIP B with ISIN code SE0003756758. Sdiptech’s preferred shares are traded under the short name SDIP PREF with...

Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Written by Customer Service on November 3, 2023. Posted in Public Companies.

Company’s T-MASK platform demonstrates ability to maximize anti-tumor efficacy and minimize systemic toxicity, and opportunities to explore broad range of cytokines and other potent therapeutics MDNA113 is a first-in-class IL-13R⍺2 targeted therapy that delivers a masked bi-specific IL-2-AntiPD1 Superkine to the tumor micro-environment where it is activated by cancer specific enzymes IL-13Rα2 is overexpressed by some of the most immunologically “cold” tumors with high unmet needs in pancreatic, liver, brain, breast and prostate cancer that annually affect over 2 million patients TORONTO and HOUSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines, today announced new preclinical data demonstrating...

Arnarlax Ehf, Has Finalized Sustainable Linked Facility Agreement With a New EUR 100 Million Bank Facility

Written by Customer Service on November 3, 2023. Posted in Public Companies.

Arnarlax ehf., a wholly-owned subsidiary of Icelandic Salmon AS, successfully signed a Sustainable Linked Facility agreement aimed at refinancing existing loan facilities. The new facility will support the company’s growth strategy and enhance operational flexibility. “We have secured a EUR 100 million sustainable linked credit facility, with a three-year tenor, through a good collaborative effort with DNB, Danske Bank, and Arion Bank” say Jónas Heiðar Birgisson, CFO and continues “Having a Sustainable Linked financing with favourable competitive terms support the company’s vision and ambition to be Icelandic Sustainable fish farmer. We are happy to continue our collaboration with DNB and Arion Bank and we look forward working with Danske bank as a strong addition to our team”. The facility encompasses...

McEwen Mining Q3 2023 Results Conference Call

Written by Customer Service on November 3, 2023. Posted in Public Companies.

TORONTO, Nov. 03, 2023 (GLOBE NEWSWIRE) — McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) invites you to join our conference call following the release of our Q3 2023 financial results on Thursday, November 9th, 2023 at 11:00 AM EST, where management will discuss our financial results and project developments and follow with a question-and-answer session. Questions for the call can be emailed in advance to info@mcewenmining.com, or can be asked directly by participants over the phone during the webcast. Q3 Results Conference Call –Thursday, November 9th, 2023, at 11:00 AM EST Calling in: Participant Toll-Free Dial-In Number: (888) 210-3454Participant Toll Dial-In Number: (646) 960-0130Conference ID: 3232920 Webcast Registration Link: https://events.q4inc.com/attendee/253960288 An archived replay of the webcast will...

AFARAK GROUP: PRODUCTION REPORT Q3 2023

Written by Customer Service on November 3, 2023. Posted in Public Companies.

15:00 London, 17:00 Helsinki, 3 November 2023 – Afarak Group SE (“Afarak” or “the Company”) (LSE: AFRK, NASDAQ: AFAGR) Production report Q3 2023 Afarak Group production during the third quarter of 2023 was higher when compared to same period of last year. In Q3 2022 we carried out extensive maintenance work, and this year we are almost back to the 2021 output. The market has weakened mainly in Europe (both demand- and margin wise) during Q3 2023, as expected and announced before. Q3/2023 Q3/2022 Change Q1-Q3/ 2023 Q1-Q3/ 2022 Change FY 2022 Speciality Alloys mt 22,305 17,790 25.4% 69,302 64,084 8.1% 87,734 Processing mt 4,998 4,417 13.2% 18,528 21,062 -12.0% 26,642 Mining mt 17,307 13,373 29.4% 50,775 43,022 18.0% 61,092 South African mines mt 61,904 17,545 252.8% 191,407 27,005 608.8% 71,271 Mining mt 61,904 17,545 252.8% 191,407 27,005 608.8% 71,271 Processing The...

America’s Car-Mart Launches 15th Annual Holiday Toy Drive

Written by Customer Service on November 3, 2023. Posted in Public Companies.

ROGERS, Ark., Nov. 03, 2023 (GLOBE NEWSWIRE) — America’s Car-Mart, Inc. (NASDAQ: CRMT) today announced its 15th annual Holiday Toy Drive to be conducted during November. The company will collect toys to share with 30 children’s hospitals. Over 150 Car-Mart dealerships in its 12-state area will serve as toy donation destinations for customers and local communities. In 2022, the company collected over 25,000 toys for 29 children’s hospitals. “For 15 years, we have conducted our Holiday Toy Drive. We are proud to have created something that is having a positive impact on thousands of children, and we are grateful for the generous donations from our associates, customers, and partners,” said Doug Campbell, Chief Executive Officer and President. “Seeing the joy on children’s faces during the holiday season makes our efforts worthwhile,...

Valoe Increases the Amount of the Convertible Bond 1/2023 from EUR 1.0 million to EUR 3.0 million and Extends the Subscription Period

Written by Customer Service on November 3, 2023. Posted in Public Companies.

Valoe Corporation Stock Exchange Release 3 November 2023 at 16.50 (Finnish time) The Board of Directors of Valoe Corporation (“Valoe” or “Company”) has resolved to increase the maximum amount of the Convertible Bond 1/2023 disclosed on 14 July 2023 by EUR 2.0 million to EUR 3.0 million. In addition, the Board of Directors of the Company has resolved to extend the subscription period of the Convertible Bond 1/2023 until 17 November 2023 at 6.00 pm Finnish time. In addition, as a result of the reverse split of the Company’s shares on 31 October 2023, the number and subscription price of the Company’s shares that can be subscribed on the basis of the Convertible Bond 1/2023 have been changed in proportion to the change in the number of all shares in the Company. In Mikkeli on 3 November 2023 Valoe Corporation BOARD OF...

Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023

Written by Customer Service on November 3, 2023. Posted in Public Companies.

Two-year results from both PROTECT and DUPLEX pivotal Phase 3 studies demonstrate treatment with sparsentan has the potential to preserve kidney function and significantly delay time to kidney failure, suggesting long-term benefits in IgAN and FSGS In PROTECT, the only head-to-head study conducted to date in IgAN, FILSPARI® (sparsentan) showed one of the slowest rates of kidney function decline in IgAN trials, consistent treatment effects across baseline eGFR and proteinuria, and higher rates of complete remission compared to maximally tolerated dose of irbesartan through 110 weeks of treatment In DUPLEX, the largest interventional study in FSGS and only study against a maximally dosed active comparator, sparsentan delivered a clinically meaningful benefit at 108 weeks with significant proteinuria reduction, higher rates of partial and...

Day: November 3, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice